Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

This is a retrospective study examining the real-world effectiveness of caplacizumab, a relatively new medication used to treat acquired Thrombotic Thrombocytopenic Purpura (aTTP) — a rare and life-threatening blood disorder where tiny clots form throughout blood vessels. Researchers are reviewing past patient records to assess how well caplacizumab worked in practice. You may be eligible if... - You have a confirmed diagnosis of an acute episode of acquired TTP - You received at least one dose of caplacizumab as part of your treatment - You are 18 years or older and have signed informed consent You may NOT be eligible if... - You have the hereditary (inherited) form of TTP, not the acquired form - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.